Vor Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vor Biopharma Inc. on July 6, 2026. The report discloses changes to the Company's Board of Directors, specifically the resignation of one director and the appointment of another.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes.
Material Changes
- Resignation: Andrew Levin, M.D., Ph.D., resigned from the Board of Directors effective immediately on July 6, 2026. The resignation was not due to any disagreement with the Company.
- Appointment: David Zaccardelli, Pharm.D., was appointed to the Board on July 7, 2026, to fill the vacancy. He serves as an independent Class II director until the 2029 annual meeting.
- Compensation: Dr. Zaccardelli will receive an annual cash retainer of $40,000. He received an initial stock option grant with a fair value of $700,000 (capped at 68,000 shares) and is eligible for annual grants of $350,000 (capped at 34,000 shares) starting in 2027.
Outlook, Risks, and Management Commentary
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management expressed gratitude to Dr. Levin for his service. Dr. Zaccardelli brings significant experience, having previously served as CEO of Verona Pharma plc (acquired by Merck in 2025) and Dova Pharmaceuticals, Inc. (acquired by Sobi in 2019).
Key Facts for Investor Verification
- Verify the effective date of Dr. Levin's resignation and the start date of Dr. Zaccardelli's term.
- Confirm the specific terms of the stock option grants, including vesting schedules and exercise prices, referenced in the Non-Employee Directors' Compensation Policy.
- Review Dr. Zaccardelli's prior roles to assess potential conflicts of interest or strategic alignment with Vor Biopharma's pipeline.
- Note that no financial data is included in this specific filing; refer to the most recent 10-K or 10-Q for financial status.